Medgenics (MDGN) Misses Q1 EPS by 10c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/22/2026
- Wall St rises on the day but falls for the week; bond yields and Iran in focus
- UBS says bull market has further to run
- S&P 500 may pull back before midterms, but Citi says buy the dip
- Global yield relief evaporates as U.S. rates push back toward multi-decade peaks
- BofA's Hartnett sees dollar slump, risk selloff if bond intervention fails
- Applied Optoelectronics sets up $600M at-the-market stock offering
- Fannie Mae loses at least 10 senior executives amid departures - WSJ
- Wall St rises on the day but falls for the week; bond yields and Iran in focus
- Morgan Stanley course-corrects their semiconductor equipment outlook on demand
- One killed, three injured when man attacks Swedish school with sword
Medgenics Reports First Quarter 2015 Financial Results
April 17, 2015 8:00 AM EDTCommenced enrollment in mid-dose arm of MDGN-201 study Initiated peritoneal dialysis study in Israel Filed U.S. IND for TARGTEPO renal anemia programs Advanced collaboration activities with CHOP Progressed TARGTCNS program with Harvard University
PHILADELPHIA, April 17, 2015 (GLOBE NEWSWIRE) -- Medgenics, Inc. (NYSE: MDGN) (the Company), the developer of a proprietary platform for the sustained production and delivery of therapeutic proteins and peptides in patients using ex vivo gene therapy and... More
